Sugi Predict

Sugi Predict / Compounds / SCHEMBL22835222

SCHEMBL22835222

SCHEMBL22835222

O=C1CCC(N2C(=O)c3cccc(NCCC4CC5(CCNCC5)C4)c3C2=O)C(=O)N1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 14/20 0.62
▸ DDB1 Q16531 12/20 0.62
▸ STAT3 P40763 2/20 0.53
▸ IKZF3 Q9UKT9 2/20 0.53
▸ TNF P01375 1/20 0.53
▸ IL1B P01584 1/20 0.53
▸ TBXA2R P21731 1/20 0.53
▸ IKZF1 Q13422 1/20 0.53
▸ HDAC1 Q13547 3/20 0.51
▸ HDAC2 Q92769 3/20 0.51
▸ MAP1LC3B Q9GZQ8 1/20 0.51
▸ HDAC3 O15379 2/20 0.50
▸ NCOR2 Q9Y618 2/20 0.50
▸ CA2 P00918 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ CHRM2 P08172 1/20 0.49
▸ OPRM1 P35372 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23672426 0.96 CRBN (0.59) CRBNDDB1STAT3IKZF3TNF
SCHEMBL23568177 0.93 CRBN (0.62) CRBNDDB1STAT3IKZF3TNF
SCHEMBL23539211 0.92 CRBN (0.65) CRBNDDB1STAT3IKZF3TNF
SCHEMBL21997810 0.91 DDB1 (0.64) CRBNDDB1STAT3IKZF3TNF
SCHEMBL21997001 0.90 CRBN (0.67) CRBNDDB1STAT3IKZF3TNF
SCHEMBL25733191 0.90 CRBN (0.60) CRBNDDB1STAT3IKZF3TNF
SCHEMBL25878614 0.88 CRBN (0.58) CRBNDDB1STAT3IKZF3TNF
SCHEMBL25894864 0.88 CRBN (0.62) CRBNDDB1STAT3IKZF3TNF
SCHEMBL23568011 0.87 CRBN (0.68) CRBNDDB1STAT3IKZF3TNF
SCHEMBL22836598 0.86 CRBN (0.63) CRBNDDB1STAT3IKZF3TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-12539295-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-03 — — US disclosed
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12150995-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-11-26 — — US disclosed
US-20240131016-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-04-25 — — US disclosed
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-02-22 — — US disclosed
EP-4271664-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-11-08 — — EP disclosed
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230101353-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-30 — — US disclosed
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-02 — — US disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 — — EP disclosed
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-07-29 — — US disclosed
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-07-29 — — US disclosed
WO-2021127190-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 — — WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 CRBN 39/4885DDB1 511/4885STAT3 167/4885
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-12539295-B2 IRAK degraders and uses thereof IRAK2, IRAK4, IRAK3 CRBN 70/4885DDB1 2951/4885STAT3 279/4885
US-20240131016-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-12150995-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 CRBN 79/4885DDB1 2480/4885STAT3 133/4885
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-20210228562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF IRAK4, IRAK2, IRAK3 CRBN 322/4885DDB1 68/4885STAT3 336/4885
US-11779578-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885
US-20230101353-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885STAT3 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.